Interestingly, a number of strategies targeting mTOR and apoptotic priming concurrently have shown promise in improving anti-cancer therapeutic responses [112,113] to tip the balance of BH3 signalling towards a pro-apoptotic phenotype. Here, MTOR is linked to cancer.